Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

Bevacizumab 40 Paclitaxel 35 Carboplatin 28 pembrolizumab 21 Cyclophosphamide 15 Specimen Handling 14 Cisplatin 13 olaparib 11 Blood Specimen Collection 11 niraparib 10 fludarabine 10 Magnetic Resonance Spectroscopy 9 Drug Therapy 9 liposomal doxorubicin 8 Topotecan 8 Taxes 8 Gemcitabine 8 Biopsy 8 Fulvestrant 7 Doxorubicin 6 cemiplimab 5 abemaciclib 5 Surveys and Questionnaires 5 Standard of Care 5 Injections 5 Fluorouracil 5 Cytoreduction Surgical Procedures 5 trastuzumab deruxtecan 4 mirvetuximab soravtansine 4 aldesleukin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Ovarian Neoplasms × Maximum Tolerated Dose × Clear all

NCT06976892 2025-08-13

IDOL

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡